The atopic dermatitis trial landscape in 2026
Atopic dermatitis is one of the most competitive therapeutic areas in immunology-driven drug development. Dupilumab's commercial success — blockbuster revenues exceeding $10B annually — has attracted every major immunology company to the space. The result is a dense, complex trial landscape with overlapping mechanisms, pediatric extensions, and aggressive head-to-head programs.
For dermatology pharma and biotech teams, keeping up with new trial registrations across IL-4/IL-13, JAK inhibitors, OX40, TSLP, IL-31, and emerging mechanisms requires systematic monitoring. DataLookout automates this work.
Get daily atopic dermatitis trial alerts
Every new biologic, JAK inhibitor, and topical trial — in your inbox each morning.
Sign Up FreeKey mechanisms generating new atopic dermatitis trials
IL-4/IL-13 dual inhibition and selective targeting
Following dupilumab (IL-4Rα), the second wave targets related cytokines with higher selectivity or improved dosing profiles. Programs include:
- Subcutaneous anti-IL-13 antibodies with monthly or less frequent dosing
- Next-generation IL-4Rα antibodies with extended half-life and self-injection devices
- Tralokinumab (IL-13 selective) follow-on combination studies
- Bispecifics combining IL-4/IL-13 with TSLP or OX40L blockade
JAK inhibitors: oral and topical
Three JAK inhibitors are approved for moderate-to-severe AD (baricitinib, upadacitinib, abrocitinib). New trial activity focuses on:
- JAK1-selective inhibitors with improved tolerability profiles
- Topical JAK inhibitors for mild-to-moderate disease (ruxolitinib cream approved; new entrants in development)
- Combination of oral JAK inhibitors with dupilumab for refractory patients
- Long-term safety extensions and real-world evidence studies
OX40 and OX40L: memory T cell targeting
OX40 pathway blockade addresses AD at the memory T cell level, potentially offering longer disease modification. Rocatinlimab (anti-OX40) is in late-stage development; amlitelimab (anti-OX40L) has shown Phase 3 data. New trials are exploring:
- Combination with IL-4/IL-13 inhibitors for refractory patients
- OX40 in pediatric populations and prevention studies
- Long-term maintenance and treatment-free remission protocols
TSLP and IL-33 upstream inhibition
Tezepelumab (anti-TSLP) showed modest activity in AD; next-generation TSLP and IL-33 programs are testing higher dose levels, pediatric populations, and combination strategies. Itepekimab (anti-IL-33) has an active AD program.
Novel topical and non-systemic approaches
For mild-to-moderate AD, the development pipeline has expanded beyond TCS/TCI to include:
- PDE4 inhibitors (crisaborole follow-ons with improved potency and tolerability)
- Aryl hydrocarbon receptor (AhR) modulators: tapinarof approved; next-generation compounds in trials
- IL-31 antagonists targeting itch specifically (nemolizumab Phase 3)
- Microbiome-targeted approaches (Staphylococcus aureus decolonization strategies)
Who monitors atopic dermatitis clinical trials?
- Dermatology business development and competitive intelligence teams at companies with AD pipelines tracking competitor enrollment and mechanism status
- Clinical development leaders designing new AD trials who need a comprehensive view of what's running in the space
- Medical affairs and MSL teams at companies with marketed AD therapies needing current competitor trial data
- Healthcare analysts covering dermatology-focused biotech and pharmaceutical companies
- Pediatric dermatologists needing to know what trials are enrolling for children with moderate-to-severe AD
Start monitoring atopic dermatitis trials today
Set your keywords once. Get daily updates automatically. Free tier available.
Get Started FreeRelated immunology and dermatology trial monitors
- Rheumatoid arthritis clinical trials — overlapping JAK inhibitor programs and shared biologics platforms
- Lupus clinical trials — shared immunology mechanisms, type I interferon biology
- Crohn's disease clinical trials — shared IL-23, JAK, and TL1A programs across immunology
333 active trials, 174 recruiting. Phases: Early Phase 1: 1, Phase 1: 35, Phase 2: 69, Phase 3: 52, Phase 4: 22.
| Top sponsor | Trials |
|---|---|
| Pfizer | 12 |
| AbbVie | 11 |
| Sanofi / Regeneron | 7 |
| Keymed Biosciences Co.Ltd | 5 |
| Eli Lilly and Company | 4 |
| Trial | Status | Latest tracked change | Seen |
|---|---|---|---|
| A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of… NCT06931990 | Recruiting | Completion pushed: 2025-12-30 → 2028-03-30 | 2026-08-28 |
| Digital Mindfulness Meditation in Adolescents With Atopic Dermatitis NCT07746427 | Recruiting | Primary endpoint(s) modified | 2026-08-25 |
| Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants Aged 6 to… NCT07660835 | Recruiting | Recruitment opened | 2026-08-15 |
| Obtaining Descriptive Classifications of Pruritus and Assessing Change in… NCT07560618 | Recruiting | Recruitment opened | 2026-08-14 |
| A Study to Observe How Pediatric Patients With Severe Atopic Dermatitis Despite… NCT06192563 | Recruiting | Enrollment increased: 150 → 230 participants | 2026-08-14 |
Each trial page shows every change DataLookout has recorded for that trial.
DataLookout checks ClinicalTrials.gov every day and records what changed on each trial: status, enrollment, phase, primary endpoint, completion dates, sites, sponsor, and the stated reason a trial stopped. Add a sponsor or a disease to your watchlist, or save any search, and the changes arrive in a daily or weekly email digest.
Free, $0 forever: 1 sponsor + 1 disease watchlist, 1 saved search with email alerts, track up to 5 individual trials, daily change detection, Trials at Risk (top trial). No credit card.
Starter, $49/month: 3 sponsor + 3 disease watchlists, 3 saved searches with email alerts, track up to 25 individual trials, full Trials at Risk list and landscape reports.
Pro, $149/month: unlimited sponsor and disease watchlists, unlimited saved searches, track unlimited individual trials, CSV export, priority email support.